for patients

State of development

Clinical development

A pilot clinical study (phase IIa) with AML (Acute Myeloic Leukaemia) patients has been performed at the Saarland University Hospital at Homburg/Saar. Primary objective was the proof of the drug’s safety. ONCOHIST is well tolerated by patients and apparently safe.

Proof of efficacy will be the objective of a following phase IIb study. However, promising enough, first signs of clinical effects were already seen among 22 patients

• 3 partial remissions
• increase of thrombocytes and normalization of leukocytes
• stabilization for several months in two patients